VJHemOnc is committed to improving our service to you

ASCO 2019 | Changes in second-line lymphoma treatment

VJHemOnc is committed to improving our service to you

Alison Moskowitz

Alison Moskowitz, MD, of the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the standard approach to relapsed/refractory lymphoma and the increased use of novel agents such as rituximab and checkpoint inhibitors in second-line therapy. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter